



Charity Number 298405
Company Number 4960054

Children with Cancer UK

Trustees' Report and Financial Statements 2016

Foreword by our Founder and Chair of Trustees

Since starting out as a small memorial charity 29 years ago, Children with Cancer UK has pioneered over 200 cutting edge research projects into the treatment of childhood cancer.

In that time we have helped improve survival rates. Children and young people are more likely to survive cancer than ever before; survival rates increasing from 63.7% in 1990 to 82.4% in 2015. Sadly however over a similar period the number of cases diagnosed has also increased. 10 families every day receive the devastating news that their child has been diagnosed with cancer.

Whilst success against some childhood cancers has improved, prognosis for other childhood cancers remains poor. Even for those cancers where more children are surviving it is crucial that we continue to invest in pioneering kinder treatments that could reduce the burden of toxicity and improve survival rates in even the hardest to treat cancers.

Progress in molecular and cellular biotechnologies has heralded the advent of an era of precision cancer medicine in which molecular genetics can be harnessed to deliver more effective, less toxic therapies. The Trustees are keen to make a major contribution to funding this technology in the UK.

We will also focus on the progress in immunotherapy of childhood leukaemia, drug delivery in childhood brain tumours and the ongoing evolution of factors involved in causation of childhood cancer. Improving treatments and survivorship has to be the key focus of research moving forward.

Our progress would not have been possible without the generosity of supporters and for that we are enormously grateful. To date, with your help, we have raised over £210 million in our fight against childhood cancer - £125 million of that in the last ten years.

A great amount has been achieved, but there is still much to be done. Without our valued supporters, vital research and welfare projects could not be funded.

I offer my heartfelt thanks to everyone who has so kindly supported our work to help more children with cancer and their families. I look forward to all we can continue to achieve together in the future.



Eddie O'Gorman OBE
Founder and Chair of Trustees

The Trustees of Children with Cancer UK present their Annual Report for the year ended 31st December 2016 under the Charities Act 2011 and the Companies Act 2006, including the Directors' Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.

Strategic Review

Review of the year – Objectives, Achievements and Future Plans

The cancer journey is an incredibly difficult journey for any child or young person to have to face. Treatment will have a huge impact on a young life and is likely to involve distressing procedures, lengthy hospital stays, toxic medicines and extended separation from family and friends. Treatment can take several years of a young life and can leave young patients with harmful long-term effects for the rest of their lives.

The research we fund gives children and families hope. Thanks to advances in research and treatment that we have helped fund, more children and young people are surviving childhood cancer than ever before.

There are now an estimated 35,000 survivors of childhood cancer alive in the UK today. This survival has been achieved through combinations of aggressive drugs, often together with radiotherapy. These treatments can have unbearable side effects that have a big impact on children and young people and can last long into adult life.

We greatly need new personalised treatments for young cancer patients that are highly targeted, more effective and less likely to have toxic side effects.

Sadly, even the strongest treatment will not be enough for one in five young patients. Tragically, cancer is still the leading killer in the U.K. of children aged one to fourteen years.

We urgently need new treatments for the young patients with high-risk cancers that currently resist all the treatments available.

Continued investment is needed so we can give all children with cancer the very best treatments that are not only more effective, but also less harmful. We want every child and young person with cancer to not only beat the disease, but to enjoy a long and healthy life.

Research highlights

We are currently funding over 60 active research projects worth over £17 million at centres of excellence around the UK.

In 2016 we made 25 new research awards totalling £4.3 million. This includes research grants for prevention, causes, treatment and education. These ranged from large project grant funding, capacity building through our fellowships and studentships and supporting specialist childhood cancer meetings.

All the research we fund is rigorously scrutinised by our Scientific Advisory Panel and reinforced by expert peer review. This ensures that we only support the highest quality research that will have the greatest impact in terms of patient care.

Information on all the projects we are funding is available on our website; here we have selected a small number of the new projects we have funded in 2016.

Development of GD2-specific Bi-specific T-cell Engagers (BiTEs) for treatment of neuroblastoma Dr Karin Straathof, UCL Great Ormond Street Institute of Child Health

Neuroblastoma is the second most common solid tumour outside of the brain and less than half of children diagnosed with the high-risk form can be cured. Current care for high-risk neuroblastoma not only causes significant side effects during treatment but also long-term issues such as impaired kidney function and fertility problems. New treatment strategies are needed to improve the cure rate and reduce the unwanted effects of treatment.

Immunotherapy is a new treatment approach which involves the use of the body's own immune cells to target cancerous cells. It has gained momentum in the treatment of leukaemia and researchers are investigating whether it can also be used to treat neuroblastoma. One form of immunotherapy is called BiTEs. BiTEs are small proteins that recruit the patient's own immune cells to the tumour where those immune cells then destroy the tumour cells.

In this project, Karin will be constructing a series of BiTEs which bind exclusively to neuroblastoma cells and act as sign posts for the immune cells to target. Her team will identify which BiTE is the most potent at facilitating the destruction of neuroblastoma tumour cells. They will extensively experiment with BiTEs of different shapes and sizes, each with differing binding properties to identify the optimal design. The second aim of the project is to determine how best to incorporate the use of BiTEs into the current treatment schedule of neuroblastoma. In other words, are BiTEs most effective at shrinking the tumour or is perhaps their optimal use preventing the tumour returning? To answer these questions the team working on this project brings together leading researchers and clinicians with unique expertise in design and development of immune cell-based treatments to develop the next generation of immunotherapy for neuroblastoma.

Treating neuroblastoma by recruiting immune cells via BiTEs may provide a completely new type of therapy and could contribute to a cure to those children who cannot be saved with conventional treatments.

Like other types of immunotherapy BiTEs have the potential to have far fewer long-term effects than is currently seen with chemotherapy and radiotherapy. If successful within the laboratory, the researchers expect to launch a clinical trial within five years and allow patients to access this experimental therapy. The success of this project could also see the use of BiTEs to treat other types of childhood cancer.

Sam

"We find the five days a month when he has steroids very challenging - but his friends are very accepting, his friends' parents very understanding and his school very accommodating. They know that it's Sam's chemo making him emotionally and physically less able and they all work together with us to help him cope. We are incredibly lucky and it has made his illness less isolating.

A while back Sam said: "Mummy, these may be the best three and a half years of my life". He's still saying that after two and a half years. So I feel, as a mum, that I am doing the best job that I can. Trying to make these years as fun as I can, so we have more happy memories than sad ones.

We are so fortunate to be treated at such an amazing hospital and to have also met some wonderful families on this journey."

Sam's mum, Tamsin

Sam was diagnosed with acute lymphoblastic leukaemia in November 2013.

Sequencing the unsequenceable: development of ground-breaking technologies to investigate the role of complex genomic sequences in childhood cancer
Professor Christine Harrison and Dr Sarra Ryan, Newcastle University

Cancer is a genetic disease and our understanding of the genetic process that leads to childhood cancer has vastly grown in recent years. However, around 10% of the human genome remains unexplored, with some of the uncharted regions believed to play a role in the development of childhood cancer. These regions have proven to be notoriously difficult to investigate in detail due to the limitation of current technologies and their ability to sequence the highly repetitive structure of DNA.

This research builds upon their previous discovery that a rare constitutional chromosomal abnormality is associated with the development of leukaemia. It is thought that this chromosomal "trigger" for leukaemia is found in the uncharted regions of the genome. The researchers will employ pioneering and revolutionary technologies to explore this region for the first time and elucidate the complete DNA sequence. They aim to identify any genetic variation that may have a biological function in the development of cancer and investigate how it may be prevented.

Christine is Professor of Childhood Cancer Cytogenetics at the Northern Institute for Cancer Research, Newcastle University. She is a world-leader in childhood leukaemia research, having played an important role in improving our understanding of childhood leukaemia genetics over the last 30 years. Sarra is a sequencing expert, who works alongside Christine in the group. Their research will involve a number of UK research institutions and will also collaborate closely with technology experts at the University of California, Santa Cruz.

Detection of genetic risk factors will help improve the prognosis of leukaemia patients through early detection and the development of new treatments.

Childhood Cancer Research Conference

2016 saw us host our fourth Childhood Cancer Conference. The conference examined how the current revolution in translational science is being harnessed to further improve survival and quality of survival for children suffering from cancer.

The three day event featured some of the world's leading scientists working in childhood cancer sharing their knowledge and expertise on Precision Medicine and Immunotherapy, and discussing the influenceable causes of childhood cancer.

What we'll be doing in 2017

In 2017 we will complete the assessment of the applications submitted under our 2016/17 Projects Grants round and continue accepting research proposals through our standard funding opportunities, Research Fellowships; Clinical Studentships, Project Grants 2017/18 and Conference & Meeting Grants.

In September we will be holding our newly reformatted scientific conference, exploring the latest state-of-the-art translational science being used in the diagnosis and treatment of childhood cancer.

We are also committed to making Precision Medicine a reality for childhood cancer patients and intend to drive forward progress through strategic investment and collaborative working.

Clinical Studentships

This is the second year of our Clinical Studentship scheme. In 2016 the remit of the scheme was broadened to fund clinicians wanting to undertake a Masters level research project (MRes). This is often a clinician's first opportunity to be exposed to high-quality research and helps focus them towards a field of speciality. This type of funding helps build capacity in childhood cancer research and also entices talented doctors to pursue a career in paediatric oncology. This strategic development was supported by the Royal College of Paediatrics and Child Health (RCPCH) which is keen to see doctors embrace and undertake high quality research. The scheme was therefore promoted by the RCPCH to maximise our exposure.

Targeting c-MYB in acute leukaemia through drug repositioning **Katherine Clesham PhD**

Although the survival rate for childhood leukaemia has significantly improved, patients who have relapsed still have a poor prognosis. These high-risk patients have to undergo more intensive treatments, causing more pronounced short- and long-term side effects. Katherine's project aims to test whether repositioned drugs (drugs not originally approved for their anti-leukaemic properties) could provide targeted and less toxic treatment for high-risk patients. The benefit of this approach is that it is considerably quicker and cheaper than developing new therapies which have to undergo more extensive clinical trials. The drugs being tested are those that are known to affect a transcription pathway relevant in leukaemia. This cellular process is responsible for the activation of genes linked to leukaemia development and maintenance. Katherine's research also aims to offer further insights into the mechanisms behind the drug activity and therefore reveal other potential targets to treat acute leukaemia.

Katherine graduated in medicine in 2005 and has been training as a haematologist since 2009. Undertaking a PhD will enable her to learn and perform scientific methods needed to undertake this vital research. She will be able to use these skills throughout her career as a consultant haematologist enabling her to be involved in clinical trials investigating novel therapies for children and young adults with acute leukaemia.

Bella-Rose

"Bella was extremely unwell when first diagnosed. In fact she was so poorly that she nearly ended up in intensive care. Our lives had stopped. I held my little girl in my arms for days, while trying to come to terms with the fact my three-year-old had cancer.

I sit in the chapel here at the hospital crying so much my tears flood the floors. I wake up during the nights crying. And Bella's consultant has told me that if she was to have a transplant she would have an 80% chance of relapsing again.

During all of this I am still training for the marathon. It gives me a purpose to what feels like a hopeless existence."

Bella-Rose's mum, Abbie

Bella-Rose was diagnosed with acute lymphoblastic leukaemia in November 2014.

Sebastian

"Sebastian has a long road ahead of him with surgery, radiotherapy and then more chemo. And then there are the effects of the radiotherapy.

He is such a good boy with a loving smile. He is getting us through and keeps us strong. He really is our superhero.

Everyone says 'I don't know how you cope', but it just becomes routine and a different way to live life. Yes, at times it is really upsetting seeing our boy in pain, but we know it's not forever and that everyone is doing their best to help him make a full recovery."

Sebastian's mum, Natasha

In October 2015 Sebastian was diagnosed with botryoid embryonal rhabdomyosarcoma.

The developmental history of bilateral neuroblastoma

Sarah Farndon MRes

Sarah aims to increase our understanding of the development of bilateral and other inherited neuroblastoma by looking at the genetic changes (mutations) that cause it and the order in which they occur.

Neuroblastoma is the second most common childhood solid cancer outside of the brain. It occurs as a result of abnormal development of cells that form part of the nervous system. Bilateral neuroblastoma is a rare variant of this condition where two tumours appear to grow at the same time on opposite sides of the body. It is unclear what causes the two tumours to arise together. Sarah's research will examine, in detail, the DNA of two children who suffered from bilateral neuroblastoma and also their families. By cross-referencing and comparing the mutations Sarah will be able to identify the mutations that occur during embryonic development which lead to tumour formation. This project will be the first attempt at understanding the life history of neuroblastoma development and could be used to provide insight into the role mutations play during embryonic development for other childhood cancers.

Sarah is a doctor currently specialising in paediatrics after graduating in 2010. This award will form the foundation of her future career in research and paediatric oncology.

Mutational dynamics and their effect on chemoresistance and metastasis in a genetically engineered model of relapsed neuroblastoma

Dr Elizabeth Calton PhD

Children diagnosed with high-risk neuroblastoma still have an exceptionally poor prognosis, with five year survival of around 50% despite intensive treatments. Despite a concerted world-wide effort to develop new drugs progress has been hampered because laboratory models do not sufficiently mimic the human disease. These differences make it much harder to test new therapies before trying them in children. Libby's research aims to produce a laboratory model that closely replicates both the pathology and molecular characteristics of the cancer as seen in actual patients. Improved models will help researchers fully understand the mechanisms involved in drug resistance and also improve the development of new cancer therapies.

Libby is a Specialty Registrar in Paediatrics and intends to further train as a childhood cancer specialist after completing her PhD research.

Brain Tumour Initiative

2016 was the final year of our Brain Tumour Initiative. It commenced with our international brain tumour workshop in February. We invited the UK's leading scientists and clinicians as well as international experts to discuss and debate the current challenges within brain tumour research.

From the lively debate and discussion it was clear that delivering targeted therapeutics into a patient's brain still represented the biggest challenge to the research community so we decided to focus the second phase of the Initiative to address this problem.

We awarded four project grants through the second phase of the Brain Tumour Initiative. These projects adopted distinctly different approaches, ranging from immunotherapy to the use of nanotechnology, to deliver therapeutics directly to where they are needed.

Brain tumour Initiative Grants

Precision delivery of chemotherapeutics across the blood-brain barrier for treatment of brain tumours

Giuseppe Battaglia

This research explores the use of engineered nanoparticles to cross the brain's natural barrier and deliver their payload of therapeutic drugs directly at the site of the tumour. These nanocarriers possess the same characteristics as natural nutrients important to the brain and so can move freely to previously inaccessible regions. They will exclusively seek out cancer cells, and once found, they will dissolve to release large amounts of therapeutic drugs that kill their target. This is particularly important for tumours that cannot be removed by surgery (like DIPG) and are reliant on therapy through drugs.

If successful this will cause dramatic improvements in survival and will also have a tremendous impact in other areas of neuro-oncology such as diagnostics and immune therapy.

Dylan C

"There are constant side effects of all the treatments including mood swings, hair falling out and mouth sores. Any sign of a temperature means he has an infection and has to be admitted to our local hospital, which has happened many times.

As I write this Dylan is in remission, but I'm fully aware that he can relapse at any time. It's hard to rejoice until all his treatment is over — I know we are all still walking on egg shells.

If anything positive has come out of Dylan's diagnosis it is all the help and support we've had from family, friends and complete strangers."

Dylan's mum, Lorraine

Dylan was diagnosed with acute lymphoblastic leukaemia in January 2015.

Convection enhanced delivery of N3-propargyl, a novel analogue of temozolomide
Beth Coyle

The chemotherapy drug (temozolomide) used to treat adult high grade gliomas is less effective in children due to a highly active repair mechanism. The aim of this project is to test the effectiveness of a more potent modification of temozolomide (N3-propargyl), which can overcome this repair mechanism. N3-propargyl will be delivered directly into the tumour using a technique called convection enhanced delivery (CED). CED allows drugs to be delivered directly into the brain through surgically implanted micro catheters. This direct approach restricts the toxic effects of the drug to the site of the tumour rather than the rest of the body. The research group, a close collaboration between Nottingham and Bristol Universities, will need to modify the drug further for use through CED and then determine the optimal dose strategy (release profile) for effectiveness. This will be undertaken in laboratory models but will have the potential to lead to a clinical trial in patients.

TCR-transduced T cells for immunotherapy of paediatric high grade glioma
John Anderson

In collaboration with the University of California, San Francisco, the researchers will use a novel immunotherapeutic approach to target diffuse midline gliomas. They aim to genetically modify cells involved in the patient's immune system to specifically target and kill childhood glioma cells whilst leaving healthy cells unharmed. The aim of this project is to perform the essential preclinical evaluations of this approach and translate the findings into clinical trials for patients in the UK and the USA.

Investigation of a harmless prokaryotic virus for intravenous targeting delivery of therapeutic nucleic acids to diffuse intrinsic pontine glioma
Amin Hajitou

Diffuse intrinsic pontine glioma (DIPG) is a type of brain tumour which is currently incurable. This project aims to use genetic engineering to reprogramme harmless bacteria viruses, to deliver therapeutic nucleic acids to DIPG cells in a preclinical setting. These viruses can readily cross the physiological brain barriers and also target tumour cells specifically, leaving normal tissue unharmed. If successful, this phage guided anticancer therapy can rapidly enter clinical trials and could also be applicable to other brainstem gliomas.

Welfare highlights

Our Welfare funding makes a huge difference to children and families affected by childhood cancer. In 2016 we were able to fund a number of exciting projects that helped make life more comfortable for children with cancer and their families.

CLIC Sargent

We continue to work with our friends at CLIC Sargent to make a big difference to families affected by childhood cancer. In 2016 we supported CLIC Sargent through their 'CLIC Sargent grants' and 'Homes from Home' initiatives.

CLIC Sargent Homes from Home offers free accommodation and support for families whilst a young person undergoes cancer treatment. The Homes from Home provide a relaxing environment where young cancer patients and their families can spend time away from a hospital ward in home style accommodation.

CLIC Sargent grants provide families with vital extra support whilst their child is undergoing cancer treatment. Parents of a child with cancer will spend, on average, over £4,000 on extra expenses during treatment. These grants help families not only with their travel costs, but extra childcare costs for siblings and higher costs of gas, electricity and food bills resulting from side effects of treatment. These grants allow families to worry about one less thing whilst their child is undergoing cancer treatment.

Bristol Children's Hospital

We are pleased to have given financial support to Bristol Children's Hospital towards a new accommodation unit, so families can stay together and be very close to the hospital when their child is undergoing cancer treatment at the hospital. This accommodation will make a huge difference to many families who may be making regular long-distance trips to the hospital and for children who may be facing months of gruelling treatment and extended stays in the hospital.

Brainstrust

We were able to provide a grant to Brainstrust to help develop a new, innovative support service for children diagnosed with a brain tumour. Little Brainstrust is able to provide coaching-led support by phone (24/7) or email, helping families overcome challenges and find the best possible outcome for their child, and their family.

Together for Short Lives

We were able to give financial support to Together for Short Lives - one of the UK's leading charities for children with life-shortening conditions. Together for Short Lives provides information and support to families of children with cancer, when a child needs palliative care.

Lifelites

We were pleased to be able to support Lifelites with a grant towards their work with young cancer patients. Lifelites provides specialist entertainment, educational and assistive technology packages to children and young people with rare, life-limiting and complex disabilities. Our grant enabled Lifelites to provide leading technology and equipment to children with cancer. The equipment encourages them to communicate, be creative and, most importantly, control elements of their lives that they might otherwise be unable.

What we're going to do in 2017

We plan to continue our welfare efforts, with a particular focus on providing support for accommodation for families near hospitals. We are also committed to making Precision Medicine a reality for childhood cancer patients and intend to drive forward progress through strategic investment and collaborative working.

Raising awareness

In September 2016, we once again took part in Childhood Cancer Awareness Month. Our aims for the month were to highlight what it's like for children, young people and families affected by childhood cancer. We also highlighted our life-saving research and the difference it makes to children and young people.

During the month we launched new, innovative online videos to showcase how important our life-saving research is - our 'Little Translators' film featured some of the children we have supported 'translate' the science behind some of our research projects. To great acclaim, one of the films was a finalist in the Charity Film Awards.

To highlight what it's like for children and young people to go through the cancer journey, we put together a series of podcasts featuring survivors of childhood cancer, a parent and a doctor talking about childhood cancer in more detail. They explained how they coped, what treatment was like and how their families managed through treatment.

We also conducted an analysis of data from the Office for National Statistics, that sadly showed a 40% increase in the numbers of children and young people being diagnosed with cancer in the last 20 years.

Brain Tumour Awareness

We campaigned for further funding into brain tumour research; working together with other charities, including Brain Tumour Research, we asked our supporters to sign a petition calling for more funding into brain tumour research. Having received over 100,000 signatures from around the UK, the petition was debated in the House of Commons and the government announced a series of new measures.

The Sun Smiles at Christmas campaign

We were delighted to have been chosen by 'The Sun' to be one of four benefitting charities for their Christmas appeal, called 'Smiles at Christmas'. As well as raising money and donating toys for children with cancer, throughout December the Sun highlighted our life-saving work through personal interviews with families we have helped support and also shared the video stories of some of the families we have supported online.

What we're going to do in 2017

We're going to ensure we reach even more people by launching a new mobile-friendly website to communicate our life-saving work in a clear way and telling the personal stories of children and families affected by childhood cancer. We're also going to optimise our social media channels to ensure we engage with families and supporters.

Fundraising highlights

London Marathon

On 24th April 2016 we saw 1,400 runners take on the gruelling 26.2 miles of the Virgin Money London Marathon. We had an incredible year of fundraising and raised over £2.8 million.

Rat Race

Over 1,000 people took part in a Rat Race Event in 2016 throughout the year, including taking part in the world's largest obstacle course "Dirty Weekend". Through their fundraising and our partnership with Rat Race, the team helped to raise over £250,000 in support of our life-saving work.

Artemis Cycle London to Edinburgh 2016

In September 2016, a group of colleagues from the company Artemis took part in a 539 mile cycle from London to Edinburgh, in aid of Children with Cancer UK.

11 team members took part in total, with a further 13 joining the team for one stage of the trip. The challenge took six days in total to complete, with them raising over £73,000 for Children with Cancer UK in the process. We would like to thank everyone at Artemis for your hard work and dedication throughout this challenge.

2016 Prudential RideLondon – Surrey 100

Over 400 cyclists cycled through the Surrey Hills and the streets of London last August and raised over £330,000 to support our work.

2016 Top Model

Top Model is the leading professional model search in the UK. The grand finalists have the opportunity to win sought-after awards and gain invaluable experience in the modelling industry.

A key part of this prestigious event is the Charity Public Vote Award, which sees finalists raising money for Children with Cancer UK. In 2016 over £35,000 was raised in support of our work.

St Baldrick's

Through our partnership with St. Baldrick's we received £55,367.07 from a series of head-shave events that took place throughout the UK in 2016. As children with cancer often lose their hair during treatment, "shavees" show their support by shaving their heads voluntarily. These events have taken place in a variety of places including pubs, restaurants and the workplace. 'Shavees' ask their friends and family to make donations 'on their head' and help to raise vital funds in support of our work.

Musical Extravaganza

The charity hosted an evening of musical entertainment at the St James Theatre in Victoria. We are very grateful to Jamie Lonsdale who both sponsored the event and organised the show. This took place on Sunday 24th April with almost 300 guests attending, including patient families and some of our researchers and raised over £27,000 for the charity.

Spring into Summer Party, Marbella

On Sunday 12th June, Sandro Morelli organised his annual Summer Party at his stunning restaurant Villa Tiberio in Marbella, helped as always by Caroline Randerson. The host for the evening was award-winning Scottish comedienne Janey Godley. Entertainment was organised by Jason Haigh-Ellery, with talented performers including stars of the West End stage Charlotte Jaconelli and Lauren Samuels. We are grateful to Caroline as well as to her friend Jenny Ingram, who organised a fashion show in the UK in May and the two events raised over £45,000 for the charity.

Opera at Syon

In 2016 we celebrated 25 years of Opera at Syon with two wonderful performances by Diva Opera of Donizetti's Don Pasquale and Mozart's Cosi fan Tutte, raising over £116,000 for the charity. The opera was performed in The Great Conservatory at Syon House, the London home of the Duke of Northumberland. On 2nd November we organised a 'thank you' drinks reception at The Honourable Society of Gray's Inn, where we also celebrated over £1.2 million raised by the event over 25 years.

The Children with Cancer Ball

Our Children with Cancer Ball raised over £610,000 in November 2016 – more than ever before. We are very grateful to all the wonderful guests who contributed to this terrific achievement, in particular the organising committee chaired by Stephen Haines. Entertainment was provided by comedian Jack Whitehall, Björn Again, opera singer Saira Luther and 'Rat Pack' singer Alan Beck and guests danced into the small hours to Rollacoaster.

Live auction highlights included a very special VIP day out for children with cancer and their families at the wonderful Grand Pier in Weston-Super-Mare and we are so grateful to the Grand Pier for hosting the day.

Zippos

Zippos Circus welcomed nearly 50 families for the sixth year, thanks to the kind donations from our supporters. Children and their families were treated as VIP guests in their very own Mini Big Top, before being taken to the Big Top for the circus extravaganza. Ringmaster, Norman Barret MBE, hosted the colourful and action-packed two hours of high-energy acts from across the world. The amazing line-up included the motorcycle Globe of Terror, world-renowned clown Mr Lorenzo, and the tumbling and human pyramids from the Kenya Boys. A great day was had by all and allowed families to make precious memories together.

Fundraising campaigns

In 2016 we continued to invest in Linda's Lottery, our new weekly lottery programme. This was possible thanks to Linda Robson, our long-term friend and Trustee who generously lent her name to this exciting fundraising initiative.

Linda's Lottery has now raised nearly £400,000 and helped to fund life-saving research into more effective and kinder treatments for childhood cancer.

What we're going to do in 2017

Our 2017 fundraising strategy will deliver a national advertising campaign to recruit new regular supporters, invest in new technologies like mobile giving, and develop existing activities like our long-standing Grand Draw raffles. These campaigns will raise the vital funds that we need to find better and safer treatments for childhood cancer, and support even more children and their families across the UK.

Corporate

One Aldwych

Since choosing us as their charity partner in 2012, One Aldwych has raised over £80,000 for our life-saving work.

To help raise awareness and funds during Childhood Cancer Awareness Month in 2016, One Aldwych's Executive Chef, Dominic Teague, invited four of his Michelin star friends to put on a once-in-a-lifetime dining experience in aid of Children with Cancer UK. Dominic was joined by Jeff Galvin of Galvin La Chapelle in London, Chris Eden of Driftwood in Cornwall, Phil Thompson of Thompson in St Albans and Tony Fleming of the soon-to-open L'Oscar Hotel in London. All proceeds from the dinner went directly to our work, raising over £9,000.

Dominic Teague, One Aldwych's Executive Chef, said:

"The evening was a chance for us chefs to give back a little. There is something particularly special when you know you are cooking for a great cause like Children with Cancer UK. It's not often that you find five top chefs in one kitchen – it's as much a rarity for us as it is for the diners. We had a great night and I hope the guests did too."

BGC

We were delighted that in 2016, we were selected as one of BGC Partners chosen charities at their annual Charity Day!

Every year, BGC Partners hold their special day dedicated to charities in memory of BGC colleagues and friends who perished in the disaster of 9/11. This amazing event is held worldwide and raises over £12 million for charities all over the globe year on year.

On the day, charities invite their celebrity ambassadors, and we were joined by Chris Eubank and Chris Eubank Jnr, and two of our patient families, The Dawson Family and The Kayum Family, who had the chance to join in on the fun and games meeting their sporting and Hollywood Heroes.

The day raised £40,000 for our vital work, which specifically contributed towards our Brain Tumour Initiative.

Coral

We were delighted that our partnership with Coral was extended throughout 2016. By the end of 2016 Coral had raised an incredible £2.2 million towards our life-saving work during their three year partnership with us. This amazing milestone was achieved thanks to Coral's team of dedicated staff, who raised money through various fundraising activities ranging from climbing Kilimanjaro to holding bake sales, taking on quizzes to hosting summer parties and Christmas parties, and holding their very own football tournament.

In addition to this fundraising activity, we have also benefitted from the sale of Coral scratch cards. Through this incentive, Children with Cancer UK receive 20% of sales of Coral's £1, £2, £5 and £10 cards, which has raised over £1 million alone for our vital work.

Steve Humphries, Central Operations Director at Coral, on visiting one of our lab tours, said:

"I found the whole day a little like being on a rollercoaster – one minute feeling huge sadness for those impacted by childhood cancer, unable to avoid putting myself in their shoes, to the next minute being totally humbled by the commitment, dedication and passion shared by the team in fighting it. Before the session I would count myself as an apostle of what you are trying to achieve, now I'm all the more so."

Andrew Reynolds' Entrepreneurs' Bootcamp

In October 2016, Brighton was the venue for the latest of the award winning Entrepreneurs' Bootcamp series of events. Hosted by self-made millionaire, Andrew Reynolds, the three day Bootcamp was attended by almost 3,000 aspiring entrepreneurs and start-up business owners.

100% of the ticket sales were donated to Children with Cancer UK and combined with additional donations during the event, a grand total of £229,842 was raised! This incredible amount will be put to extremely good use in our fight to save even more young lives.

Andrew Reynolds, Founder of Andrew Reynolds' Entrepreneurs' Boot Camp tells us "Spending three days with 3,000 aspiring entrepreneurs - each of whom had donated their ticket money to this amazing charity - was an incredibly humbling experience. One that we hope to repeat in 2017 too."

How your donations help children with cancer

We always adhere to the UK regulatory framework (in 2016 the FRSB and Fundraising Regulator). Children with Cancer UK is committed to best practice in fundraising and follows the Fundraising Promise and the Institute of Fundraising's Code of Fundraising Practice.

Our Fundraising Promise

The Fundraising Promise is a key part of the FRSB scheme. It outlines how we, as a member, will behave when undertaking our fundraising and ensures fundraising is legal, honest, open, transparent and accountable.

We are committed to high standards

We are honest and open

We are clear

We are respectful

We are fair and reasonable

We are accountable

Our Supporter Care Charter

We recognise the true value of each and every supporter

We respect our supporters

We value supporter relationships

We know who our supporters are

We listen to our supporters' feedback

We go "The Extra Mile"

Thank you

A very special and heartfelt thank you to all the families who have kindly shared their experiences in 2016. Your involvement is essential in raising awareness and vital funds to help children with cancer.

Although we are only able to highlight a very small number of our supporters below, we offer our sincere and wholehearted thanks to everyone who so generously supported our work during 2016:

All our runners and challenge participants

The team at London Marathon Events

Our dedicated Ball and Opera at Syon chairs and committees, notably Stephen Haines, Margrete Hargreaves-Allen and Lady Julia Craig Harvey

Caroline Randerson for the fashion show and Spring into Summer Party in Marbella

Martin Burton and Zippos Circus

Cos Onisiforou and John Durden of Fare and Harbour & Jones for generous catering at our Zippos Circus event

Sandro Morelli at Villa Tiberio in Marbella

Kerry Michael and The Grand Pier in Weston-Super-Mare for hosting our event for families in April.

Jim Mee and the team at Rat Race Events

Sanrio

RBI Visual

Our Scientific Advisors and specialist peer reviewers

And finally, a special thank you to our dedicated team at Children with Cancer UK.

Fundraising Friends:

Ant and Dec • Brian Blessed • Brenda Blethyn • Frank Bruno • Sir Michael Caine • Jasper Carrott
Dame Joan Collins • Phil Collins • Dame Judi Dench • Kian Egan • Philippa Forrester • Sir Bruce Forsyth
Sir Chris Hoy • Chris Jarvis • Sir David Jason • Pui Fan Lee • Lennox Lewis • Gary Lineker • Joanna Lumley
Sandy Lyle • Sir Paul McCartney • Sir Trevor McDonald • Stephen Mulhern • Des O'Connor • Robert Powell
Pauline Quirke • Sir Steve Redgrave Linda Robson • Jonathan Ross • Phillip Schofield • Chris Tarrant
Rob Templeman • David Tennant • Kevin Whately • Holly Willoughby • Paul Young

Financial review

The Consolidated Statement of Financial Activities (SOFA) set out on page 28, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.

Our income in 2016 is £16.5 million and, whilst this is less than last year's total of £17.5 million, we have increased our net income for the year to £2.4 million from last year's deficit of £532,444. This has increased our reserve position to be £10.8 million (2015: £8.4 million) and the rationale for this is explained on page 18.

We are pleased with our financial performance during the year, especially with the fundraising challenges experienced by the Charity sector - particularly within individual giving. Our fundraising objectives for the year have been to maintain the fundraising performance of previous years so that we are able to continue to award between £5 million and £6 million in grants.

We have been able to broadly achieve these aims and, as can be seen in note 4, we have maintained or exceeded previous year's fundraising income, except for the scratch card partnership we have with the Gala Coral Group. This partnership is in its final stages and we had anticipated lower income levels in 2016. We have observed growth in our corporate, trusts and major donor income streams and expect this to grow in 2017 as a result of continued investment. We have also benefited from a number of large legacies this year making the total of £1.9 million (2015: £850,000) a record level for legacy income. This has contributed to the increase in net income, along with the scaling back of cold recruitment of new supporters through postal appeals.

We have continued to invest in having a greater presence in online and mainstream media, to secure additional sustainable income as well as create awareness of our cause. The £1.4 million investment this year, in addition to the £1.7 million last year, has led to at least 12,000 new regular givers that will bring significant income in over the long-term, as well as a significant exposure in the public domain. Whilst the expenditure has been realised in the current year, income will accrue over coming years.

We have continued to carry out our regular seasonal direct mail appeals and, although we have found it more challenging, have maintained steady income at just over £4 million. We have scaled back our cold recruitment of new supporters compared to previous years and are currently evaluating our approach in light of the new Fundraising Regulator. This year's expenditure includes further investment in our Weekly Lottery activity to provide regular players of the charity's raffle. This has now broken even and will lead to additional sustainable income in future years.

Our sports events team has once again exceeded our expectations to become one of our most consistent income streams with income of £4.3 million. Much of this income is raised through the charity purchasing places in the London Marathon and other sporting events and allocating these to fundraising participants. Therefore, expenditure is incurred in advance of income being received.

We have continued our recent momentum in research and welfare funding and have maintained our financial commitment at close to £5.5 million in direct charitable funding. We are expecting to award a similar level of grant funding in coming years and have a reserve balance to give us the buffer to guarantee this funding.

For every £1 donated, we spend 82p on fighting childhood cancer

- 47p on research projects
- 14p on welfare projects
- 21p on raising awareness

We invest 18p in £1 to raise more money.

For every £1 we spend on fundraising, we raise over £5 more.

Reserves

At the end of the year, the charity held £10,829,380 (2015: £8,430,813) in unrestricted reserves.

Unrestricted reserves are generated when the supporter does not stipulate how the income may be spent. They are therefore available to be applied at the discretion of Trustees to any of the charity's charitable purposes. It is the intention of Trustees to expend these funds as soon as possible whilst using them in a structured manner to meet their long term objectives.

The Trustees consider the reserves to have a dual role; to provide a buffer to allow operating expenditure to be carefully minimised should the need arise, as well as facilitate the following year's grant award programme of at least £6 million. The remainder, approximately £4.8 million, is set aside for fluctuations in income that could impact the charity's ability to carry out its services. The Trustees consider that, as this amount is within the range of 25% and 35% of the current year's income, this is a reasonable buffer to have in place as a contingency.

Going Concern

The charity has a strong reserve position and has sufficient available resources, as demonstrated by the reserve policy above. We have adequate financial resources and are well placed to manage the business risks. Our planning process, including financial projections, has taken into consideration the current economic climate and its potential impact on the various sources of income and planned expenditure.

Our cash deposits could easily be drawn down should working capital be required. We believe that there are no material uncertainties that call into doubt the charity's ability to continue. The accounts have therefore been prepared on the basis that the charity is a going concern.

Investments

The Memorandum of Association allows the charity to deposit or invest funds in any manner but to invest only after obtaining such advice from a financial expert as the Trustees consider necessary and having regard to the suitability of investments and the need for diversification.

The charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposits, to meet fluctuating needs.

The charity currently holds £10.4 million of investments held for the longer term. This comprises £1.6 million in an investment portfolio managed by Barclays Investment Managers and £8.7 million in cash deposits. The charity also holds £10.3 million in short term investments comprising £6 million in fixed term deposits and the remainder in instant access deposits.

Cash balances generally are increasing over time since more funds are being kept available to meet longer term grant commitments. The Trustees are keen to ensure that these funds are not exposed to any risk since this cash value has already been promised to grant holders. As at 31st December 2016, our grant liabilities are close to £12 million (2015: £9.5 million).

Risk and internal control

The Trustees have overall responsibility for ensuring that the charity has an appropriate system of controls, financial and otherwise. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

Trustees' Report

For the year ending 31st December 2016

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the Charity or for publication is reliable; and
- the Charity complies with relevant laws and regulations.

As part of the charity's risk management process the Trustees acknowledge their responsibility for the charity's system of internal control and reviewing its effectiveness. It is also recognised by the Trustees that such a system is designed to manage rather than eliminate the risk of failure to achieve the charity's objectives and can only provide reasonable, not absolute, reassurance against material misstatement or loss.

The Trustees keep under regular review the major risks that could affect their achievement of the Charity's objectives. The charity also periodically engages professional advisers to facilitate the charity's risk assessment process.

Principal risks and uncertainties

The Charity's main risk is our susceptibility to changes in the economic and financial environment. We do not receive any funding from the government and rely solely on discretionary donations from the public – therefore adverse economic conditions can impact our ability to maximise fundraising. However, we have contingency plans and a stable reserve position in place to minimise such risks.

A significant risk for the Charity is our reliance on two major income streams that make up the majority of our annual income: individual giving and running events. We have been continuing to diversify our income streams to manage this and are developing sustainable income streams such as committed and major donor giving.

A further risk is the impact of adherence to the new Fundraising Regulator and planned General Data Protection Regulator. With the appointment of a Head of Compliance and Stewardship, who has the remit to review our practices to ensure compliance, we hope to have mitigated this risk.

The principal risk for the trading subsidiary is its reliance on short term and ad hoc commercial arrangements to generate income. We are investing in improving our merchandising and trading income streams to manage this risk

Structure, governance and management

The financial statements comply with current statutory requirements, the Memorandum and Articles of Association, Statement of Recommended Practice (SORP FRS 102) and current accounting standards (FRS 102).

Governing documents

These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.

Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11th November 2003 as amended by special or written resolutions, dated 30th November 2004, 22nd December 2006, 12th May 2007 and 28th July 2016. On 14th May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK.

Trustees' Report For the year ending 31st December 2016

However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11th May 2011.

The charity operates under its Trust Deed (dated 4th January 1988) and Variation of Trust Deed (dated 10th December 2003).

Aims and Objectives

Purposes and Aims

The charity's objects as amended by written resolution of 12th May 2007, and 28th July 2016 are shown below:

- i) To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
- ii) To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
- iii) To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.

Our aims are to determine the causes, find the cure and provide care for children with cancer.

We fund life-saving research into the causes, prevention and treatment of childhood cancer.

We fund innovative welfare projects to provide better care for young cancer patients and their families.

We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.

We are a member of the Association of Medical Research Charities.

We are also a member of the National Cancer Research Institute.

Further details of the projects we fund are detailed in note 21.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a total of five members (2015: four). The Trustees of the charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

Trustee appointment and induction

There was one new appointment to the Trustee Board in 2016 (2015: none). The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.

Trustees' Report For the year ending 31st December 2016

Each new Trustee receives the Charity Commission publication 'The Essential Trustee: What you need to know' as well as the most recent published annual report. The Chief Executive offers an induction day to all Trustees which provides full information about the operations of the charity.

Management

The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive and the senior management team. The Chairman and Chief Executive also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.

The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.

Following Cliff O'Gorman's appointment as Honorary Chief Executive Officer from Jan 8th to April 6th a request was made to the Charity Commission for Cliff to be Chief Executive Officer and remunerated from Jan 8th and consent was duly given. Please see Note 18 for further information.

Remuneration

The salaries of Children with Cancer UK staff are periodically benchmarked against other charities to ensure that salary levels are in line with industry averages and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of the industry and organisational needs, as well as individual and charity performance.

In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.

During 2016 the charity has been compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.

Trading Subsidiaries

Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all profits are donated under Gift Aid.

The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship and commercial agreements.

The trading activities generated profit for the year of £70,383 (2015: £76,778) which will be paid to Children with Cancer UK under the Gift Aid Scheme. It is anticipated that the trading activity within the subsidiary will continue at a similar level during the current year.

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Related parties

An internal conflict of interest register is in place which is based on declaration of interests submissions completed by all Trustees and senior management. Trustee meeting policy is that, where Trustees have an interest in the matter under discussion, they will absent themselves from these discussions and decisions.

Grant making policy

It is the Trustees' policy to maximise the proportion of its charitable output that is achieved through grant making.

• Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2016, a total of £1,034,596 (2015: £1,129,620) was awarded to welfare projects.

• Research grants

An increasing proportion of the charity's output is achieved through scientific and medical research. The charity adheres to the standards set by the Association of Medical Research Charities (AMRC) and awards research grants after deliberation and approval of its own Scientific Advisory Panel. In 2016, a total of £4,137,717 (2015: £4,388,744) was awarded to research projects.

Project funding in these areas is directed in two ways:

1. Research into treatment

The charity works in partnership with Bloodwise, Great Ormond Street Hospital Children's Charity, University College London, Cancer Research UK and other institutions giving grants in support of the parts of their programmes that are relevant to the charity's objects.

2. Research into prevention and causes

The charity advertises for project applications that are then subject to peer review and scrutiny by our panel of scientific advisors before the Trustees determine which projects to support.

It is also the Trustees' policy to support directly a number of long-term programmes of research at UK institutions in areas which are of wide ranging importance in relation to childhood cancer.

The Trustees openly invite research applications and the criteria are displayed on our website as well as by advertisements in scientific publications.

Plans for future periods

The charity has strengthened its reputation as a funder of translational research and has received an increase in the quantity and quality of science it's been asked to fund. In order to develop and maintain our funding streams and investment in research and welfare projects, the charity has put together a set of strategic imperatives.

1. We will aim to be the biggest annual financial contributor to research into childhood cancer in the UK
2. We will fund high quality research aimed at developing treatments which are not only more effective but less debilitating and disruptive to young lives
3. We will maintain a place in the top 100 UK charities for fundraising
4. We will contribute to peer reviewed research into the discovery and reduction of probable carcinogens as identified on the WHO monograph list
5. We will provide capital funding to encourage the development of centres of excellence in childhood cancer research
6. We will raise public awareness about our activities and the results of relevant research
7. We will seek to influence the development of policy to promote the best interests of children with or at risk of cancer

Trustees' Report

For the year ending 31st December 2016

8. Our welfare activity will be in supporting residential homes and associated financial support for families affected by childhood cancer
9. We will deliver a highly engaged and effective organisation that recognises and rewards the right behaviour, innovation and outcomes for the charity and those we help

In 2018 the charity will be 30 years old. In order to build on the success of recent years, the charity plans on making the most of this significant milestone by celebrating the life-saving research and welfare work it has funded and continues to fund and the impact of its work.

With GDPR coming into force in May 2018 and in light of the new Fundraising Regulations, a Head of Compliance and Stewardship has been appointed. She will be reviewing policies, procedures, the need for documentation as well as fundraising practices. She will be working with, Trustees, Senior Staff and other relevant staff to ensure that the charity is compliant.

The Charity Commission has issued new guidance for Trustees - CC20. This details the legal and best practice requirements and raises points that the charity is working towards and will be put into place during 2017. The details of which will be outlined for discussion in the Trustees' meetings.

The trading subsidiary will continue to operate on the same scale and no significant changes are planned.

Reference and administration

Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA) was set up in memory of Paul O'Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees

The Trustees of Children with Cancer UK are the charity's Trustees under charity law and the directors of the charitable company:

Eddie O'Gorman OBE (founder and Chair of Trustees)
The Rt Hon the Earl Cadogan KBE DL
Sandra Mileham
Linda Robson
Alasdair Philips (appointed 10th September 2016)

Chief Executive

Caroline Blakely (Resigned 12th January 2016)
Cliff O'Gorman (Appointed 8th January 2016)

Senior Management

Cliff O'Gorman (Chief Executive)
Ben Twyman (Head of Events)
Pippa Gough (Head of Compliance and Stewardship)
Emma Sheard (Head of Individual Giving)
Camelia Vasilcan (Head of IT Operations)
Mark Hooley (Head of Communications)

Registered Charity Number

298405

Registered Company Number

4960054

Trustees' Report
For the year ending 31st December 2016

Principal office

51 Great Ormond Street, London WC1N 3JQ

Solicitors

Bates Wells Braithwaite, 2-6 Cannon Street, London EC4M 6YH

Auditors

Crowe Clark Whitehill LLP, St Bride's House, 10 Salisbury Square, London EC4Y 8EH

Bankers

National Westminster Bank plc, 30 North Audley Street, London W1A 4UQ

Contact details

Children with Cancer UK

51 Great Ormond Street, London WC1N 3JQ

Tel: 020 7404 0808

Fax: 020 7404 3666

Email: info@childrenwithcancer.org.uk

www.childrenwithcancer.org.uk

Scientific Advisory Panel

We are indebted to the members of our Scientific Advisory Panel who freely give their time and expertise to help drive forward our fight against childhood cancer.

Research into childhood cancer is a broad field and we aim to reflect the diversity of the field amongst the membership of our Panel:

Professor Silvia Marino MD, FMH-Path. Professor of Neuropathology and Honorary Consultant Neuropathologist, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London.

Dr Yann Jamin BSc (Hons), PhD. Paul O'Gorman Postdoctoral Fellow, The Institute of Cancer Research

Professor Pamela Kearns MBChB, BSc (Hons), PhD, FRCPCH. Professor of Clinical Paediatric Oncology, School of Cancer Sciences, University of Birmingham; Honorary Consultant in Paediatric Oncology, Birmingham Children's Hospital
Resigned from the panel on 29th September 2016.

Dr Matthew Murray MB BChir, MA, FRCPCH, DCH, PGCME, PhD. Academic Consultant Paediatric Oncologist, Addenbrooke's Hospital; University Lecturer, University of Cambridge

Mr Charles Stiller. Lead on Childhood Cancer, National Cancer Intelligence Network, Public Health England

Professor David Walker BMedSci, BM, BS, FRCP, FRCPCH (Chair). Professor of Paediatric Oncology, Children's Brain Tumour Research Centre, University of Nottingham; Honorary Consultant in Paediatric Oncology, Nottingham Children's Hospital (QMC Campus NUH NHS Trust).

Dr Owen Williams BSc (Hons), PhD. Reader in Cancer Biology and Head of Cancer Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust.

Statement of Trustees' responsibilities

The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company's auditor in connection with preparing the audit report) of which the charitable company's auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 19th July 2017 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:



Eddie O'Gorman OBE
Founder and Chair of Trustees

Date 19th JULY 2017

Independent Auditor's Report to the Trustees of Children with Cancer UK

We have audited the financial statements of Children with Cancer UK for the year ended 31 December 2016 which comprise the Group Statement of Financial Activities, the Group and Company Balance Sheets, the Group Cash Flow Statement and the related notes numbered 1 to 20.

The financial reporting framework that has been applied in their preparation is applicable law and FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland.

This report is made solely to the charitable company's Trustees, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the company's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of Trustees and auditor

As explained more fully in the Statement of Trustees' Responsibilities, the Trustees (who are also the directors of the charitable company for the purpose of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charitable company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the Trustees; and the overall presentation of the financial statements.

In addition, we read all the financial and non-financial information in the Strategic report and the Trustees' Annual Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the charitable company's affairs as at 31 December 2016 and of the group's income and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion based on the work undertaken in the course of our audit the information given in the Strategic Report and the Trustees' Annual Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate accounting records; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.



Pesh Framjee
Senior Statutory Auditor
For and on behalf of
Crowe Clark Whitehill LLP
Statutory Auditor
London

Date *28 July 2017*

**Consolidated statement of financial activities for the year ended 31 December 2016
(incorporating an income and expenditure account)**

	Note	Total restricted funds £	Total unrestricted funds £	Total 2016 £	Total 2015 £
Income from:					
Donations and legacies	4	303,238	15,279,183	15,582,421	16,666,630
Other trading activities	4	-	750,973	750,973	728,190
Income from investments		-	142,735	142,735	139,814
Other income		-	48,287	48,287	9,630
Total Income	17	303,238	16,221,178	16,524,416	17,544,264
Expenditure on:					
Raising funds		-	2,520,561	2,520,561	3,465,102
Charitable activities	8	1,842	11,798,945	11,791,787	14,573,438
Total Expenditure	6,16	1,842	14,310,506	14,312,348	18,038,540
Net change in investments	10	-	186,499	186,499	(38,168)
Net income/(expenditure)		301,396	2,097,171	2,398,567	(532,444)
Transfers between funds	17	(301,396)	301,396	-	-
Net movement in funds		-	2,398,567	2,398,567	(532,444)
Reconciliation of funds:					
Total funds brought forward		-	8,430,813	8,430,813	8,963,257
Total funds carried forward	17	-	10,829,380	10,829,380	8,430,813

The comparative figures for each fund are shown in note 3 to the financial statements.

Trustees' Report
For the year ending 31st December 2016

Balance sheets as at 31 December 2016
Company Number: 4960054

	Note	2016 Group £	2016 Charity £	2015 Group £	2015 Charity £
Fixed assets					
Investments	10	10,417,452	10,417,552	11,855,726	11,855,826
		10,417,452	10,417,552	11,855,726	11,855,826
Current assets					
Debtors and prepayments	12	2,351,499	2,387,565	2,185,935	2,227,396
Cash deposits		10,272,332	10,272,332	4,118,836	4,118,836
Cash at bank and in hand		402,077	366,152	519,967	476,630
		13,025,908	13,026,049	6,824,738	6,822,862
Creditors: amounts falling due within one year					
Grants	13,14	(6,303,885)	(6,303,885)	(3,657,849)	(3,657,849)
Other	14	(678,968)	(679,209)	(812,755)	(810,979)
Net current assets	16	6,043,055	6,042,955	2,354,134	2,354,034
Total assets less current liabilities		16,460,507	16,460,507	14,209,860	14,209,860
Creditors: amounts falling due after more than one year					
Grants	13	(5,631,127)	(5,631,127)	(5,779,047)	(5,779,047)
Net assets		10,829,380	10,829,380	8,430,813	8,430,813
Represented by:					
Unrestricted funds		10,829,380	10,829,380	8,430,813	8,430,813
Restricted funds		-	-	-	-
	16,17	10,829,380	10,829,380	8,430,813	8,430,813


The net income for the financial year dealt with in the financial statements of the parent Charitable company was £2,398,567 (2015: £(534,444)).

The notes on pages 31 to 45 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 19th July 2017.



The Rt Hon the Earl Cadogan KBE DL
Trustee



Eddie O'Gorman OBE
Trustee

Consolidated cash flow statement for the year ended 31 December 2016

	Note	2016 £	2015 £
Cash flows from operating activities:			
Net cash provided by operating activities	a)	4,454,597	1,440,501
Cash flows from investing activities:			
Dividends and interest from investments		142,735	139,814
Net cash provided by investing activities		142,735	139,814
Change in cash and cash equivalents in the reporting period			
		4,597,332	1,580,315
Cash and cash equivalents at the beginning of the reporting period	b)	16,494,529	14,914,214
Cash and cash equivalents at the end of the reporting period	b)	21,091,861	16,494,529

Notes to the Cash flow Statement

a) Reconciliation of net (expenditure) to net cash flow from operating activities	2016 £	2015 £
Net (expenditure) for the reporting period	2,398,567	(532,444)
Adjustments for:		
Dividends, interest and rents from investments	(142,735)	(139,814)
Decrease/(increase) in debtors	(164,848)	(85,359)
Increase in creditors	2,363,613	2,198,118
Net cash provided by (used in) operating activities	4,454,597	1,440,501

b) Analysis of cash and cash equivalents	1 January 2016 £	Cashflow £	31 December 2016 £
Cash at bank and in hand	519,967	(117,890)	402,077
Cash held as short term investments	4,118,836	6,153,496	10,272,332
Cash held as long term investments	11,855,726	(1,438,274)	10,417,452
	16,494,529	4,597,332	21,091,861

Notes to the financial statements for the year ended 31 December 2016

1. Charity information

Children with Cancer UK is a private limited company (registered number 4960054), which is incorporated and domiciled in the UK. The address of the registered office is 51 Great Ormond Street, London WC1N 3JQ. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation, limited by guarantee and therefore with no share capital.

2. Accounting policies

(a) Basis of preparation

The financial statements have been prepared in accordance with the Charities SORP FRS 102 applicable to charities preparing their accounts in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland, the Companies Act 2006 and UK Generally Accepted Practice as it applies from 1st January 2015.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.

The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as 'the Group'. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity's financial instruments.

(b) Preparation of the accounts on a going concern basis

After making enquires, the Trustees have a reasonable expectation that the charity has adequate resources to continue its activities for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the financial statements as outlined in the Statement of Trustees Responsibilities on page 26. There are no material uncertainties casting doubt on going concern.

(c) Financial Instruments

The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group's trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group's short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including bonds and cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within income and expenditure. Investments in subsidiary undertakings are held at cost less impairment.

(d) Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

Residuary legacies – The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

(e) Functional/Presentational currency

The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.

(f) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

(g) Incoming resources
Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity,

Trustees' Report
For the year ending 31st December 2016

or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.

Income from trading activities is recognised in the period in which the service has been provided or product sold.

Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.

(h) Expenditure and basis of allocation of costs

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 6 of the financial statements.

Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

(i) Taxation

Children with Cancer UK, as a registered charity, is exempt from taxation of income falling within Section 505 of the Taxes Act 1988 or section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that this is applied to its charitable objectives. No tax charge has arisen in the year.

(j) Tangible fixed assets

Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.

(k) Pension scheme

Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Scottish Widows. In 2016, the charity made a contribution of 8% (2015: 8%) of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.

(l) Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

(m) Gifts in Kind

Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.

The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.

3. Consolidated statement of financial activities for the year ended 31 December 2015

	Total restricted funds £	Total unrestricted funds £	Total 2015 £
Income from:			
Donations and legacies	572,366	16,094,264	16,666,630
Other trading activities	-	728,190	728,190
Income from investments	-	139,814	139,814
Other income	-	9,630	9,630
Total Income	572,366	16,971,898	17,544,264
Expenditure on:			
Raising funds	-	3,465,102	3,465,102
Charitable activities	220,668	14,352,770	14,573,438
Total Expenditure	220,668	17,817,872	18,038,540
Net change in investments	-	(38,168)	(38,168)
Net (expenditure)/income	351,698	(884,142)	(532,444)
Transfers between funds	(351,698)	351,698	-
Net movement in funds	-	(532,444)	(532,444)
Reconciliation of funds:			
Total funds brought forward	-	8,963,257	8,963,257
Total funds carried forward	-	8,430,813	8,430,813

4. Income

	2016 £	2015 £
Donations and legacies		
Appeals and associated donations	4,074,561	4,159,183
Committed giving	1,499,086	1,527,699
Community fundraising	779,890	752,895
Corporate and trust donations	1,500,989	812,480
Legacies (see contingent asset below)	1,887,778	849,849
Sports events	4,367,323	4,349,183
	14,109,627	12,451,289
Scratch cards (see scratch card income below)		
	1,472,794	4,215,341
	15,582,421	16,666,630
Other trading activities		
Events	736,111	716,131
Sale of merchandise	14,862	12,059
	750,973	728,190

Contingent asset – legacy income

As at 31 December 2016, the charity had been notified of a further five residuary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £104,224 which has not

Scratch card income

The scratch card income relates to the sale of gambling products as part of a corporate partnership with the Gala Coral Group Ltd. As part of the agreement, the charity receives 20% of the sales proceeds of the scratch card. However, as the product was launched under the charity's Gambling Commission license, the charity has recognised 100% of the sales proceeds as income and 80% as expenditure.

5. Lottery income

As part of the charity's Gambling Commission License (Non Remote License - 000-004700-N-306402-010) (Remote License – 000-004700-R-308531-010), during the year the charity has operated three lotteries, a weekly lottery and charity scratch card.

The following ticket sales were received for each lottery where the draw was held in 2016:

	Ticket Sales
	£
Weekly Lottery	288,046
Christmas Raffle (draw 5th February 2016)	735,703
Spring Raffle (draw 12th May 2016)	486,255
Summer Raffle (draw 12th September 2016)	492,628
Total	2,002,632

As the Christmas raffle spans two accounting periods, £217,589 was received during 2016 and £507,705 during 2015. All other ticket sales were received during 2016 only. All ticket sales have been included within the total income for 2016 and 2015.

As explained in Note 4, the charity operates a scratch card with Gala Coral Group Ltd acting as the external lottery manager. Six scratch cards were launched on 21st October 2014 with an expiry date of 31st March 2016 and a further two were made available on 3rd July and 14th August 2015 expiring on 31st December 2016. The total sales of these scratch cards amounted to £5,430,833. These sales have been included within the total income for 2016, 2015 and 2014 as follows:

	2016	2015	2014	Total
	£	£	£	£
Gross Sales	597,419	4,215,340	618,074	5,430,833
Prizes and Management Fee	477,935	3,372,272	494,459	4,344,666
Net Sales	119,484	843,068	123,615	1,086,167

6. Total expenditure

	Expenditure on raising funds	Expenditure on charitable activities	Support on governance costs	2016 Total	2015 Total
	£	£	£	£	£
Staff costs	307,613	678,754	553,707	1,540,074	1,450,583
Charitable expenditure	-	10,557,536	-	10,557,536	13,501,137
Mailing / Campaign costs	914,336	-	-	914,336	1,570,860
Event costs	962,447	-	-	962,447	1,240,204
Other expenditure	133,943	-	169,813	303,756	241,877
Audit fee	-	-	34,200	34,200	33,880
	2,318,339	11,236,290	757,720	14,312,348	18,038,540

7. Support costs

Support costs are split as follows:

	Support costs £	Governance costs £	2016 Total £	2015 Total £
Staff costs	502,436	51,271	553,707	484,048
Other expenditure	169,813	-	169,813	127,419
Audit fee	-	34,200	34,200	33,880
	672,249	85,471	757,720	645,347

Central office overheads are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month by month basis throughout the year. Overheads and staff costs are then allocated to the various charitable activities below based on this staff time basis.

8. Costs of charitable activities

	Activities undertaken directly £	Grant funding of activities £	Support and governance costs £	2016 Total £	2015 Total £
Research into Prevention & Causes	1,277,511	1,030,846	42,918	2,361,275	2,613,230
Research into Treatment	1,338,602	3,106,869	42,156	4,487,627	4,445,171
Welfare	894,804	1,034,596	46,689	1,976,089	3,023,309
Education	2,697,140	194,180	85,476	2,976,796	4,491,728
	6,208,057	5,366,491	217,239	11,791,787	14,573,438

8. Results of the parent charity

	2016 £	2015 £
Total income	16,721,040	17,539,526
Total expenditure	(14,322,472)	(18,071,970)
Net income	2,398,568	(532,444)

10. Investments

	2016 £	2015 £
Listed investments (see below)	1,629,077	1,443,482
Cash deposits	8,788,375	10,412,244
	10,417,452	11,855,726
Market value of listed investments at 1 Jan	1,443,482	1,493,154
Additions to investment portfolio	460,679	-
Disposals to investment portfolio	(460,795)	-
Investment manager fees	(13,784)	(11,504)
Net Investment gain/(loss)	199,495	(38,168)
Market value of listed investments at 31 Dec	1,629,077	1,443,482
Listed Investments comprise the following:		
Cash and short maturity bonds	41,093	35,144
Developed Government bonds	16,080	15,619
High Yield and Emerging Market Bonds	79,371	39,603
Investment Grade Bonds	60,206	97,510
Developed Market Equities	1,095,802	972,413
Emerging market equities	127,843	90,233
Real estate	157,346	109,424
Multi class and other investments	51,336	83,536
Total listed investments at 31 Dec	1,629,077	1,443,482
Total Investments are listed in:		
United Kingdom	1,580,399	891,777
Overseas	48,678	551,705
	1,629,077	1,443,482

Investment in subsidiary

Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship. Any taxable profits made by Helping Children with Cancer Limited are donated to Children with Cancer UK under Gift Aid.

Trustees' Report
For the year ending 31st December 2016

The income and expenditure for the year ended 31 December 2016 is as follows:

	2016	2015
	£	£
Income	83,028	90,530
Cost of sales	-	(160)
Administrative expenses	(12,645)	(13,592)
Profit on ordinary activities before gift aid and taxation	70,383	76,778

The balance sheet for the subsidiary as at 31 December 2016 are as follows:

	2016	2015
	£	£
Assets	102,195	118,970
Liabilities	(102,095)	(118,870)
Reserves	100	100

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Current asset investments are held in cash on deposit for the current and prior year.

11. Trustees' emoluments

The Trustees received no remuneration or reimbursement of expenses during the year (2015 Nil).

12. Debtors

	2016	2016	2015	2015
	Group	Charity	Group	Charity
	£	£	£	£
Trade debtors	48,135	44,298	84,359	75,753
Amounts due from subsidiary undertakings	-	97,775	-	113,920
Other debtors	426,334	426,334	734,300	734,300
Accrued income	458,162	400,290	209,250	145,397
Prepayments	1,418,868	1,418,868	1,158,026	1,158,026
	2,351,499	2,387,565	2,185,935	2,227,396

13. Grants to third parties

	2016 £	2015 £
Outstanding liabilities at the start of the year	9,436,896	7,451,417
Awarded during the year (note 20):		
Research into prevention and causes	1,030,847	1,319,875
Research into treatment	3,106,870	3,068,899
Welfare	1,034,596	1,129,620
Raising awareness	194,180	-
	5,366,493	5,518,394
Under-spends on previous grant awards	(600,735)	(126,246)
Paid during the year	(2,267,642)	(3,405,383)
Foreign exchange loss	-	(1,286)
Outstanding liabilities at the end of the year	11,935,012	9,436,896
Grants falling due within one year	6,303,885	3,657,849
Grants falling due after more than one year	5,631,127	5,779,047
	11,935,012	9,436,896

The restatement of the foreign grant creditors resulted in an unrealised foreign exchange loss of nil (2015: £1,286).

14. Creditors: amounts falling due within one year

	2016 Group £	2016 Charity £	2015 Group £	2015 Charity £
Accruals and deferred income	635,972	631,652	779,667	774,717
Taxes and social security	42,996	42,996	33,088	33,088
Amounts due to subsidiary undertakings	-	4,561	-	3,174
	678,968	679,209	812,755	810,979
Grants payable	6,303,885	6,303,885	3,657,849	3,657,849
	6,982,853	6,983,094	4,470,604	4,468,828

15. Deferred income

Deferred income comprises income received in advance for entries to our weekly lottery.

	2016 Group £	2016 Charity £	2015 Group £	2015 Charity £
Balance as at 1 January 2016	30,968	30,968	56,524	56,524
Amount released to income from donations	(30,968)	(30,968)	(56,524)	(56,524)
Amount deferred in year	52,383	52,383	30,968	30,968
Balance as at 31 December 2016	52,383	52,383	30,968	30,968

16. Analysis of net assets between funds

	2016 Group Restricted funds £	2016 Group Unrestricted funds £	2016 Group Total funds £	2015 Group Total funds £
Fixed assets	-	10,417,552	10,417,552	11,855,726
Net current assets	-	6,042,955	6,042,955	2,354,134
Creditors falling due after more than one year	-	(5,631,127)	(5,631,127)	(5,779,047)
Net assets at the end of the year	-	10,829,380	10,829,380	8,430,813

Trustees' Report
For the year ending 31st December 2016

17. Statement of funds

	At the start of the year £	Total Income £	Total Expenditure £	Transfers £	At the end of the year £
Restricted funds					
Professor Richard Grundy. BIOMarkers of Ependymomas in Children and Adolescents (BIOMECA) - Integrated Biological study within SIOP Ependymoma II trial organised by European Ependymoma Biology Consortium	-	245,498	-	(245,498)	-
Professor John Anderson, UCL Great Ormond Street Institute of Child Health, TCR-transduced T cells for immunotherapy of paediatric high grade glioma	-	1,520	(1,520)	-	-
Helen E Bryant, University of Sheffield, Novel therapies for MYCN-amplified neuroblastoma	-	122	(122)	-	-
Professor Andrew Peet, Institute of Child Health, University of Birmingham. Non-invasive identification of medulloblastoma genetic subtypes using metabolite profiles and imaging features	-	8,800	-	(8,800)	-
Dr Juan Pedro Martinez Barbera, UCL Great Ormond Street Institute of Child Health, Molecular Characterisation and Assessment of Potential Biomarkers and Novel Drug Targets for Childhood Craniopharyngioma	-	5,000	-	(5,000)	-
Dr Steven Pollard, University of Edinburgh. Genome editing of human neural stem cells using nuclease-assisted gene targeting: a tool to uncover the function of H3F3A mutations in paediatric glioma	-	3,000	-	(3,000)	-
Professor Persis Amrolia, Great Ormond Street Hospital. Immunotherapy with CD19 CAR redirected T cells for relapsed paediatric ALL (CARPALL)	-	50	-	(50)	-
Anglers Against Cancer, contribution towards welfare	-	200	(200)	-	-
Professor Shai Izraeli, Sheba Medical Centre. Hematopoietic transcription factors and childhood leukaemia - Down syndrome as a model	-	28	-	(28)	-
Professor David Grimwade, King's College London. Molecular tracking of treatment response in paediatric AML	-	39,020	-	(39,020)	-
	-	303,238	(1,842)	(301,396)	-
Unrestricted funds	8,430,813	16,221,178	(14,310,506)	301,396	10,829,380
Total funds	8,430,813	16,524,416	(14,312,348)	-	10,829,380

Note The restricted funds comprise donations that were to be spent on specific causes and projects.

All other restricted income was either discharged during the year or transferred from restricted back to unrestricted funds. This has occurred when restricted funds were received towards grants that were previously paid out of unrestricted reserves.

18. Staff costs

	2016 £	2015 £
Salaries and wages	1,300,099	1,228,115
National Insurance	137,278	127,416
Pension	102,697	95,052
	1,540,074	1,450,583

During 2016, one employee was paid a gross salary between £80,000 and £90,000 (2015: none) and one employee has been paid a gross salary between £60,000 and £70,000 (2015: one).

There have been 6 (2015: 7) positions that have formed part of the senior leadership team. The total remuneration including pension contributions for these employees amounts to £452,548 (2015: £362,412).

In addition to the management section on page 21, an employee that is connected to a Trustee was paid £89,008 gross salary and £7,667 pension contributions (2015: £33,750 gross salary and nil pension contributions). There is no interdependence between the Trustee and the connected person.

The average weekly number of contracted employees during the year was as follows:

	2016 No.	2015 No.
Charitable Activities	4	4
Raising Funds	23	22
Support, Governance, Operations and Administration	9	10
	36	36

19. Related Party Transactions

There have been no other related party transactions during the year other than those with the trading subsidiary.

The charity has carried out various transactions during the year with its trading subsidiary, Helping Children with Cancer Limited. Income of nil (2015: £1,114) of trading subsidiary income was initially received in the charity's bank accounts and then transferred. Expenditure of £60 (2015: £1,038) was paid by the charity on behalf of the trading subsidiary and then recharged. A management fee of £5,000 (2015: £5,000) has been charged to the trading subsidiary for use of the charity's trademarks and a further £3,985 (2015: £4,014) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). The trading subsidiary's taxable profit of £70,383 (2015: £76,778) will be donated to the charity under Gift Aid. As at 31st December 2016, £4,561 (2015: £3,174) was owed to the trading subsidiary from the charity and, conversely, £97,775 (2015: £113,920) owed to the charity from the trading subsidiary. The outstanding balances and gift aid due will be discharged by the trading subsidiary during 2017.

20. Financial Instruments

The financial statements include the following in respect of items:

	2016 £	2015 £
Financial assets measured at amortised cost	848,362	635,854
Financial liabilities measured at amortised cost	(12,519,318)	(10,185,595)
Financial assets measured at fair value	21,091,861	16,494,528

The entity's income, expense, gains and losses in respect of financial instruments are summarised below:

Total interest income for financial assets held at fair value	142,735	148,899
---	---------	---------

Trustees' Report
For the year ending 31st December 2016

21. Grants to third parties

	Research into prevention and causes 2016 £	Research into treatment 2016 £	Welfare 2016 £	Education 2016 £	Total 2016
Dr Maria Vinci, Institute of Cancer Research, The role of interclonal communication and the tumour microenvironment in driving paediatric GBM and DIPG migration and invasion	413,545				413,545
Dr Amin Hajitou, Imperial College London, Investigation of a harmless prokaryotic virus for intravenous targeting delivery of therapeutic nucleic acids to DIPG		333,809			333,809
CLIC Sargent, To fund Paul's Fund, which provides much needed financial assistance to the families of children being treated for cancer			332,596		332,596
Professor Giuseppe Battaglia, University College London, Precision delivery of chemotherapeutics across the blood-brain barrier for treatment of brain tumours		327,500			327,500
Professor John Anderson, UCL Great Ormond Street Institute of Child Health, TCR-transduced T cells for immunotherapy of paediatric high grade glioma		323,585			323,585
Dr Elizabeth Coyle, University of Nottingham, Convection enhanced delivery of N3-propargyl, a novel analogue of temozolomide		258,845			258,845
Professor Chris Jones, Institute of Cancer Research, The role of histone H4K20 methylation in paediatric glioblastoma and DIPG	258,458				258,458
Professor Persis Amrolia, Great Ormond Street Hospital (via GOSH Children's Charity), Immunotherapy with CD19 CAR redirected T cells for relapsed paediatric ALL (CARPALL). Extension of grant awarded in 2014		253,824			253,824
Professor Louis Chesler, The Institute of Cancer Research, Development of experimental models and therapeutic strategies to target treatment-resistant, metastatic neuroblastoma		251,989			251,989
Dr Karin Straathof, UCL Great Ormond Street Institute of Child Health, Development of GD2-specific Bi-specific T-cell Engagers (BiTEs) for treatment of neuroblastoma		251,392			251,392
Dr Elizabeth Calton, Institute of Cancer Research, Mutational dynamics and their effect on chemoresistance and metastasis in a genetically engineered model of relapsed neuroblastoma			250,000		250,000
Bristol Children's Hospital, 'Keeping Families Together', to provide family accommodation at Bristol Children's Hospital		250,000			250,000
Dr Katherine Clesham, UCL Great Ormond Street Institute of Child Health, Targeting c-MYB in acute leukaemia through drug repositioning		249,999			249,999
Dr Marc Tischkowitz, University of Cambridge, Investigating microRNA processing genes in rhabdomyosarcomas and other DICER1-related childhood tumours	225,510				225,510
Dr Suzanne Turner, University of Cambridge, CRISPR-based genome-wide knockout and overexpression screens to identify acquired resistance mechanisms to ALK inhibition in neuroblastoma		223,310			223,310
Professor David Walker, University of Nottingham, Children's Brain Tumour Drug Delivery Consortium				194,180	194,180
Together for Short Lives, To provide help for young people and their families with cancer to ensure that they have the best quality care and support from the moment of diagnosis			180,000		180,000
Brainstrust, Expanding an effective brain tumour support service for children and their parents			152,000		152,000
Professor Ruth Jarrett, University of Glasgow, Evaluation of CCL17 as a diagnostic biomarker for classical Hodgkin lymphoma		149,968			149,968
Professor Louis Chesler, The Institute of Cancer Research, Molecularly guided treatment in childhood cancer		125,666			125,666
Lifelites, To help enhance the lives of children with cancer in hospices through the use of specialist technology			120,000		120,000
Dr Sarah Farndon, UCL Great Ormond Street Institute of Child Health, The developmental history of bilateral neuroblastoma	65,311				65,311
Professor Christine Harrison, Newcastle University, Sequencing the unsequenceable: development of ground-breaking technologies to investigate the role of complex genomic sequences in childhood cancer	55,022				55,022
Dr Helen Bryant, University of Sheffield, Novel therapies for MYCN-amplified neuroblastoma		49,300			49,300
Dr Ian Carr, University of Leeds, Identification of MSH6 null individuals in patients suspected of suffering from Constitutional Mismatch Repair Cancer Syndrome		31,587			31,587
Dr Mathuros Ruchirawat, Chulabhorn Research Institute, The 8th Princess Chulabhorn International Science Congress	12,000				12,000
Professor David Walker, University of Nottingham, An international workshop to develop a web based paediatric pre-operative cerebellar mutism risk stratification tool		10,000			10,000
Dr Rod Mitchell, University of Edinburgh, 1st UK Fertility Preservation Annual Meeting		8,975			8,975
Dr Ruman Rahman, University of Nottingham, Brain Tumour Initiative – Drug delivery development grant		5,000			5,000
Dr Evon Poon, Institute of Cancer Research, Advances in Neuroblastoma Research Congress 2016		2,120			2,120
Professor Terry Dwyer, University of Oxford, International Childhood Cancer Cohort Consortium (I4C) Meeting 2016		1,000			1,000
Total grants to third parties	1,030,846	3,106,869	1,034,596	194,180	5,366,491